8-(6-((9-((1r,4r)-4-methylcyclohexyl)-9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)-1,8-diazaspiro[4.5]decan-2-one | 1588959-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 8-(6-((9-((1r,4r)-4-methylcyclohexyl)-9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)-1,8-diazaspiro[4.5]decan-2-one
• CAS: 1588959-04-9
• 化学式: C₂₉H₃₄N₈O
• 分子量: 510.642
• InChiKey: VCQXPLQAUTUUTC-MXVIHJGJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.12
• 重原子数：
  38.0
• 可旋转键数：
  4.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  100.86
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为产物：
  描述：

  5-(3-fluoropyridin-4-yl)-N⁴-((1R,4R)-4-methylcyclohexyl)pyrimidine-2,4-diamine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 lithium hexamethyldisilazane 、 sodium t-butanolate 作用下， 以 N-甲基吡咯烷酮 、 甲苯 为溶剂， 生成 8-(6-((9-((1r,4r)-4-methylcyclohexyl)-9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)-1,8-diazaspiro[4.5]decan-2-one
  参考文献：
  名称：

  Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3

  摘要：

  We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3(WT)) and induced cell death in MOLM13 (FLT3(ITD)) and even in MOLM13 (FLT3(ITD, D835Y), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.

  DOI：

  10.1021/jm500118j

文献信息

• Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
  作者：Zhihong Li、Xianghong Wang、John Eksterowicz、Michael W. Gribble、Grace Q. Alba、Merrill Ayres、Timothy J. Carlson、Ada Chen、Xiaoqi Chen、Robert Cho、Richard V. Connors、Michael DeGraffenreid、Jeffrey T. Deignan、Jason Duquette、Pingchen Fan、Benjamin Fisher、Jiasheng Fu、Justin N. Huard、Jacob Kaizerman、Kathleen S. Keegan、Cong Li、Kexue Li、Yunxiao Li、Lingming Liang、Wen Liu、Sarah E. Lively、Mei-Chu Lo、Ji Ma、Dustin L. McMinn、Jeffrey T. Mihalic、Kriti Modi、Rachel Ngo、Kanaka Pattabiraman、Derek E. Piper、Christophe Queva、Mark L. Ragains、Julia Suchomel、Steve Thibault、Nigel Walker、Xiaodong Wang、Zhulun Wang、Malgorzata Wanska、Paul M. Wehn、Margaret F. Weidner、Alex J. Zhang、Xiaoning Zhao、Alexander Kamb、Dineli Wickramasinghe、Kang Dai、Lawrence R. McGee、Julio C. Medina

  DOI：10.1021/jm500118j

  日期：2014.4.24

  We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3(WT)) and induced cell death in MOLM13 (FLT3(ITD)) and even in MOLM13 (FLT3(ITD, D835Y), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.